A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Abstract Mebendazole is used extensively for treatment of local gut helminthic and invasive echinococcus infections. Anticancer effects of mebendazole have been shown in experimental cancer models and in case studies in patients with advanced cancer. Given these observations, the aims of this study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. Mansoori, M. Fryknäs, C. Alvfors, A. Loskog, R. Larsson, P. Nygren
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0e6899635f1f4dc08e23f090c9d52184
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0e6899635f1f4dc08e23f090c9d52184
record_format	dspace
spelling	oai:doaj.org-article:0e6899635f1f4dc08e23f090c9d521842021-12-02T16:55:45ZA phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer10.1038/s41598-021-88433-y2045-2322https://doaj.org/article/0e6899635f1f4dc08e23f090c9d521842021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88433-yhttps://doaj.org/toc/2045-2322Abstract Mebendazole is used extensively for treatment of local gut helminthic and invasive echinococcus infections. Anticancer effects of mebendazole have been shown in experimental cancer models and in case studies in patients with advanced cancer. Given these observations, the aims of this study were to investigate safety and efficacy of individualized dosed mebendazole in the cancer indication. Patients with treatment refractory gastrointestinal cancer were treated with individualized dose adjusted mebendazole up to 4 g/day to target a serum concentration of 300 ng/ml. Efficacy and safety were assessed by CT-scans, clinical surveillance and blood sampling. Eleven patients were included in the study and 10 started the treatment phase. Two patients stopped treatment prior to and the remaining eight after tumour evaluation by CT-scan at 8 weeks, all due to progressive disease. Four patients also fulfilled criteria suggested for hyperprogression. Only five patients reached the target serum-mebendazole concentration. No severe adverse effects were observed. Individualized dose adjusted mebendazole is safe and well tolerated in patients with advanced cancer but all patients experienced rapid progressive disease. New approaches such as prodrug development and combination with other anticancer drugs seem needed for further exploration of mebendazole as an anticancer drug.S. MansooriM. FryknäsC. AlvforsA. LoskogR. LarssonP. NygrenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q S. Mansoori M. Fryknäs C. Alvfors A. Loskog R. Larsson P. Nygren A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
description	Abstract Mebendazole is used extensively for treatment of local gut helminthic and invasive echinococcus infections. Anticancer effects of mebendazole have been shown in experimental cancer models and in case studies in patients with advanced cancer. Given these observations, the aims of this study were to investigate safety and efficacy of individualized dosed mebendazole in the cancer indication. Patients with treatment refractory gastrointestinal cancer were treated with individualized dose adjusted mebendazole up to 4 g/day to target a serum concentration of 300 ng/ml. Efficacy and safety were assessed by CT-scans, clinical surveillance and blood sampling. Eleven patients were included in the study and 10 started the treatment phase. Two patients stopped treatment prior to and the remaining eight after tumour evaluation by CT-scan at 8 weeks, all due to progressive disease. Four patients also fulfilled criteria suggested for hyperprogression. Only five patients reached the target serum-mebendazole concentration. No severe adverse effects were observed. Individualized dose adjusted mebendazole is safe and well tolerated in patients with advanced cancer but all patients experienced rapid progressive disease. New approaches such as prodrug development and combination with other anticancer drugs seem needed for further exploration of mebendazole as an anticancer drug.
format	article
author	S. Mansoori M. Fryknäs C. Alvfors A. Loskog R. Larsson P. Nygren
author_facet	S. Mansoori M. Fryknäs C. Alvfors A. Loskog R. Larsson P. Nygren
author_sort	S. Mansoori
title	A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
title_short	A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
title_full	A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
title_fullStr	A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
title_full_unstemmed	A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
title_sort	phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0e6899635f1f4dc08e23f090c9d52184
work_keys_str_mv	AT smansoori aphase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT mfryknas aphase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT calvfors aphase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT aloskog aphase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT rlarsson aphase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT pnygren aphase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT smansoori phase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT mfryknas phase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT calvfors phase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT aloskog phase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT rlarsson phase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer AT pnygren phase2aclinicalstudyonthesafetyandefficacyofindividualizeddosedmebendazoleinpatientswithadvancedgastrointestinalcancer
_version_	1718382781072932864

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Ejemplares similares